Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-01-23 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about an upcoming Board Meeting scheduled for January 31, 2025, where the company will consider unaudited financial results for the quarter and nine months ended December 31, 2024. It references Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements, which pertains to board meeting disclosures. The document does not contain any financial data or results itself, nor does it include detailed financial analysis or reports. It is an announcement of a board meeting, not the meeting materials or financial results. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about a board meeting and upcoming financial results disclosure.
2025-01-23 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement informing stock exchanges about the USFDA inspection of a subsidiary's manufacturing facility and the resulting observations. It references a previous disclosure and provides an update on the facility's operational status. The document is short (1467 characters) and serves as a notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed audit information. It is primarily a compliance and regulatory disclosure under SEBI regulations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-16 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the cancellation and dematerialization of physical share certificates for the quarter ended December 31, 2024. It is a compliance certificate related to share dematerialization and does not contain financial statements, management discussion, or other report content. The document is short (2833 characters) and is a regulatory compliance certificate rather than a financial report or announcement of voting results, capital changes, or management changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory compliance documents that do not fit other specific categories.
2025-01-15 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the closure of the trading window for insiders ahead of the announcement of quarterly financial results. It does not contain any financial data, results, or detailed report content. It is an announcement related to insider trading compliance and timing of financial results disclosure, not the financial results or report itself. The document length is only 1597 characters, which is quite short and fits the pattern of a regulatory announcement rather than a full report. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such compliance and procedural announcements.
2024-12-24 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about a credit rating affirmation and outlook revision by India Ratings and Research Private Limited for Jubilant Pharmova Limited. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is an update on credit rating, not a financial report, earnings release, or management discussion. It is a regulatory announcement about credit rating changes, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update or Interest Rate Update. The document length is short and it is an announcement rather than a report itself.
2024-12-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.